Edition:
United Kingdom

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.07EUR
15 Dec 2017
Change (% chg)

€0.14 (+15.19%)
Prev Close
€0.93
Open
€0.97
Day's High
€1.19
Day's Low
€0.95
Volume
18,400,829
Avg. Vol
797,361
52-wk High
€1.19
52-wk Low
€0.64

Summary

Name Age Since Current Position

Jean Stephenne

67 2012 Independent Chairman of the Board, representing Innoste SA

Eduardo Bravo Fernandez de Araoz

2011 Chief Executive Officer, Managing Director, Executive Director

Claudia D'Augusta

2011 Chief Financial Officer, Chief Compliance Officer, Company Secretary

Wilfried Dalemans

Chief Technology Officer

Gil Beyen

51 Chief Business Officer, Managing Director, Executive Director, representing of Gil Beyen BVBA

Dirk Buescher

2013 Director

Jose Terencio

2013 Director

Willy Duron

72 2012 Independent Director

Russell Greig

64 2012 Independent Director

Eduard Holdener

72 2011 Independent Director

Dirk Reyn

52 2011 Independent Director, representing R&S Consulting BVBA

Biographies

Name Description

Jean Stephenne

Mr. Jean Stephenne has been Independent Chairman of the Board, representing Innoste SA, of Tigenix NV since September 19, 2012. Mr. Stephenne was until April 2012 Member of the Corporate Executive Team of GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre, Belgium. He currently serves as Chairman of BESIX, IBA, Vesalius Biocapital, Nanocyl, Bepharbel, BioWin and Welbio, and as Board Member of BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Lambert (GBL), Helse, Uteron and OncoDNA. He used to serve as Board Member of Auguria Residential Real Estate Fund, which is currently in liquidation. He is Member of the Company's Audit Committee.

Eduardo Bravo Fernandez de Araoz

Mr. Eduardo Bravo Fernandez de Araoz is Chief Executive Officer, Managing Director and Executive Director of Tigenix NV since May 3, 2011. He has more than 20 years experience in the pharmaceutical industry. He held several senior management positions at Sanofi-Aventis, including Vice President for Latin America, a division with 2000 employees and sales of more than EUR 1 billion. At Sanofi-Aventis he also held senior positions in Marketing and Sales for Europe and he was General Manager for Belgium. Prior to his tenure at Sanofi-Aventis, Mr. Bravo spent seven years at SmithKline Beecham in sales positions both nationally and internationally. Mr. Bravo holds a degree in Business Administration and a Masters of Business Administration (INSEAD), and is co-Chair of the Alliance of Advanced Therapies.

Claudia D'Augusta

Ms. Claudia D'Augusta is Chief Financial Officer, Chief Compliance Officer and Company Secretary of Tigenix NV since May 3, 2011. Ms. D’Augusta has more than fifteen years of experience in the field of corporate finance. After completing her degree in Economics and a Doctorate in Philosophy in Business Administration at the University of Bocconi, Italy, she joined the Corporate Finance Department of Deloitte & Touche in Milan. She later joined Apax Partners in Madrid where she participated in the origination and execution of M&A transactions. She was subsequently Finance Director of Aquanima (Santander Group). Ms. D’Augusta was Member of the Board of Directors of Sensia S.L. from April 2005 until April 2008.

Wilfried Dalemans

Mr. Wilfried Dalemans is Chief Technology Officer of Tigenix NV. Mr. Dalemans holds a Doctorate in Philosophy in Molecular Biology from the Universities of Hasselt and Leuven. Before joining the Company, he held several senior management positions at GlaxoSmithKline Biologicals, Belgium. As Director of Regulatory Strategy and Development, he was responsible for the worldwide registration activities of GlaxoSmithKline’s Flu franchise. Mr. Dalemans has also been Director of Molecular Biology and Research, responsible for the development of nucleic acid and tuberculosis vaccines, as well as the immunology research activities. Prior to joining GlaxoSmithKline, he worked at Transgène, France, where he was in charge of the cystic fibrosis research program. Mr. Dalemans currently serves as Supervisory Director of Arcarios B.V. and Director of Arcarios NV.

Gil Beyen

Mr. Gil Beyen is Chief Business Officer, Managing Director and Executive Director, representing of Gil Beyen BVBA, of Tigenix NV. He joined the Board of Directors on September 15, 2003. He gained a Master of Science in Bioengineering from the Katholieke Universiteit Leuven (Belgium) in 1984 and obtained a Masters of Business Administration from the University of Chicago (United States) in 1990. He founded the Company in 2000 and served as Chief Executive Officer of the Company until 2011. Before founding the Company, Mr. Beyen worked as a management consultant at Arthur D. Little (ADL) in Brussels. Before commencing his Masters of Business Administration, he worked three years as a research engineer in environmental biotechnology. Since June 2012, Mr. Beyen is Chairman of the Supervisory Board at Erytech Pharma SA, a French biopharmaceuticals company. He also is manager of Axxis V&C BVBA, as well as Member of the Board of BIO.be, and commissioner for the Flemish government on the board of the Flemish Institute of Biotechnology (VIB).

Dirk Buescher

Dr. Dirk Buescher, Ph.D., is Director of Tigenix NV effective December 5, 2013. He is Chief Executive Officer of Gri-Cel SA. Previously he was Vice President R&D of Cellerix. Dr. Buescher obtained his Doctorate in Philosophy in biology and immunology from the University of Hannover, Germany, and as a postdoc specialized in molecular developmental biology and stem cell research at the Salk Institute in La Jolla, California. He is a member of the board of directors of VCN Biosciences and Araclon Biotech.

Jose Terencio

Dr. Jose Terencio, Ph.D., is Director of Tigenix NV effective December 5, 2013. He is Chief Operating Officer of Gri-Cel SA. Previously he was Director R&D of Laboratorios Grifols. Before that he was at the R&D center of Grupo Ferrer. With more than 18 years of experience in the pharmaceutical industry, Dr. Terencio has particular knowledge in drug discovery and the development of small molecule therapeutics. Dr. Terencio obtained his Doctorate in Philosophy in CNS Pharmacology from the University of Barcelona. He is a member of the board of directors of VCN Biosciences.

Willy Duron

Mr. Willy Duron is Independent Director of Tigenix NV since September 19, 2012. He was first appointed as Director on February 26, 2007. He was the Company’s Chairman from September 2007 to September 2012. He started his career at ABB Verzekeringen in 1970, becoming Member of the executive committee in 1984. Mr. Duron holds a Master of Science degree in Mathematics from the University of Gent and a Master of Science degree in Actuarial Sciences from the Katholieke Universiteit Leuven. He currently is a member of the board of directors of Ravago NV, Vanbreda Risk & Benefits NV, Universitaire Ziekenhuizen Leuven, Universitair Centrum St Jozef Kortenberg, Agfa-Gevaert NV and Van Lanschot Bankiers NV. Previously, Mr. Duron was Chief Executive Officer of KBC Groep NV and KBC Bankverzekeringsholding NV, Chairman of the board of Argosz, Secura, ADD and W&K, as well as member of the board of directors of KBC Asset Management NV, Synes NV, CSOB, Warta, FBD and Amonis. He serves as Chairman of the Company's Audit Committee.

Russell Greig

Dr. Russell G. Greig, Ph.D., has been Independent Director, representing Greig Biotechnology Global Consulting, Inc., of Tigenix NV since September 19, 2012. He worked at GlaxoSmithKline for nearly three decades, most recently as President of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served as President of GSK’s Pharmaceuticals International from 2003 to 2008 and also on the GSK Corporate Executive Team. Dr. Greig currently serves as Chairman of AM Pharma in the Netherlands, Isconova AB in Sweden and Syntaxin in the UK, and as Board Member of Ablynx in Belgium and BioAlliance Pharma in France. He is also Member of the Scottish Science Advisory Council and of the BioQuarter Board (Scotland), and is Venture Partner at Kurma BioCapital (Paris, France). He holds a Bachelor of Science and a Doctorate in Philosophy (Biochemistry) from University of Manchester. He is Member of the Company's Nomination and Remuneration Committee.

Eduard Holdener

Dr. Eduard Enrico Holdener is Independent Director of Tigenix NV since May 3, 2011. Dr. Holdener earned his medical degree from the University of Zurich (November 1971) and held the post of Chief Medical Officer & Global Development Head in the Pharma Division of F. Hoffmann-La Roche Pharmaceutical Ltd until February 2008. In that function Dr. Holdener was also part of the F.Hoffmann-La Roche AG Pharma and Corporate Executive Committee. He began his career in pharmaceuticals in 1986 after 14 years of working at various hospitals and academic institutions in Switzerland and the United States. During his tenure at Roche, he was credited with winning approval for an important number of new medicines in different therapeutic areas. Dr. Holdener currently acts as Chairman of NovImmune S.A, Director of Parexel International Co and HBM Healthcare Investments, Non-Executive Director of Syntaxin Ltd and Member of the Board of Swiss Cancer Research Foundation. Dr. Holdener has also been Board Member of Cellerix since 2008. He holds a Doctorate of Medicine from Basel University (1975). He was Member of the Audit Committee and currently serves as Member of the Company's Nomination and Remuneration Committee.

Dirk Reyn

Mr. Dirk Reyn is Independent Director, representing R&S Consulting BVBA, of Tigenix NV since May 3, 2011. Mr. Dirk Reyn obtained his Pharmacist degree at the University of Antwerp, and holds a Masters of Business Administration degree from the Northwestern University of Chicago (Kellog's). Mr. Reyn is Managing Director of Shire-Movetis. He founded Movetis NV in 2006 where he served as Chief Executive Officer and Executive Director until the company was acquired by Shire in 2010. Mr. Reyn served as the Head of the GI Strategic Marketing group for many years and then Vice President New Business Development for Janssen-Cilag in Europe. He has more than 25 years of experience, having first joined Johnson & Johnson in 1992 and became the driving force behind the global marketing and commercial strategy for such products as PREPULSID and PARIET and other compounds from the GI portfolio. Prior to joining Johnson & Johnson, he served in a number of national and international commercial positions at Eli Lilly. Mr. Dirk Reyn holds board positions in non-pharma companies Horizon Pharmaventures, R&R Promotions and BbyB Chocolates. He is Chairman of the Company's Nomination and Remuneration Committee.